Generalized anxiety disorder Trials in Oklahoma City, United States
Conditions / Generalized anxiety disorder / Oklahoma City, United States
Generalized anxiety disorder has been the subject of sustained clinical investigation across multiple research sites.
16 total trials for this combination
Showing top 10 of 16 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00329264 | Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder | COMPLETED | PHASE3 |
| NCT05729373 | A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder | COMPLETED | PHASE2/PHASE3 |
| NCT06701903 | Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | RECRUITING | PHASE2 |
| NCT00735267 | A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD) | TERMINATED | PHASE3 |
| NCT00481325 | Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder | COMPLETED | PHASE2/PHASE3 |
| NCT01629966 | Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder | COMPLETED | PHASE3 |
| NCT00329446 | Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder | COMPLETED | PHASE3 |
| NCT03829241 | Randomized Trial of Adult Participants With Generalized Anxiety Disorder | COMPLETED | PHASE3 |
| NCT00616655 | Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects | COMPLETED | PHASE2 |
| NCT00731120 | Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder | COMPLETED | PHASE3 |